Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines-Reference-Cited by-同舟云学术

Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines

Published:2024-09 Issue:22 Volume:42 Page:126010
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Lustig Yaniv^ORCID,Barda Noam,Weiss-Ottolenghi Yael,Indenbaum Victoria,Margalit Ili,Asraf Keren,Doolman Ram,Chalkias Spyros,Das Rituparna,Elfatarany Gamal,Harats Dror,Kreiss Yitshak,Regev-Yochay Gili

Funder

Moderna

Sheba Medical Center

Publisher

Elsevier BV

Reference15 articles.

1. Use of updated COVID-19 vaccines 2023–2024 formula for persons aged >/=6 months: recommendations of the advisory committee on immunization practices - United States, September 2023;Regan;MMWR Morb Mortal Wkly Rep,2023

2. Interim recommendations from the advisory committee on immunization practices for the use of bivalent booster doses of COVID-19 vaccines - United States, October 2022;Rosenblum;MMWR Morb Mortal Wkly Rep,2022

3. A bivalent omicron-containing booster vaccine against Covid-19;Chalkias;N Engl J Med,2022

4. JN.1: the present public health concern pertains to the emergence of a novel variant of COVID-19;Khan;Environ Health Insights,2024

5. Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86;Yang;Lancet Infect Dis,2023

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risks of Severe Acute Respiratory Syndrome Coronavirus 2 JN.1 Infection and Coronavirus Disease 2019–Associated Emergency Department Visits/Hospitalizations Following Updated Boosters and Prior Infection: A Population-Based Cohort Study;Clinical Infectious Diseases;2024-06-26